Showing 4091-4100 of 5623 results for "".
- LumiThera Purchases MacuLogix Assetshttps://modernod.com/news/lumithera-purchases-maculogix-assets/2481007/LumiThera announced the purchase of the assets of MacuLogix. Terms of the deal were not disclosed. MacuLogix is the developer of the wearable AdaptDX Pro dark adaptometer, which allows eye care professionals to measure dark adaptation—designed to dia
- Aerie Pharmaceuticals Announces First Patient Dosed in the COMET-3 Study of AR-15512 for the Treatment of Dry Eye Diseasehttps://modernod.com/news/aerie-pharmaceuticals-announces-first-participant-dosed-in-the-comet-3-study-of-ar-15512-for-the-treatment-of-dry-eye-disease/2481006/Aerie Pharmaceuticals announced that the first participant has been dosed in the phase 3 registrational “COMET-3” study to evaluate AR-15512 ophthalmic solution as a treatment for the signs and symptoms of dry eye disease (DED). COMET-3 is the second of three trials in the p
- EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Maintenance Treatment of Wet AMDhttps://modernod.com/news/eyepoint-pharmaceuticals-announces-first-patient-dosed-in-phase-2-davio-2-clinical-trial-of-eyp-1901-for-the-maintenance-treatment-of-wet-amd/2481005/EyePoint Pharmaceuticals, Inc., announced that the first patient has been dosed in the Phase 2 Durasert® and Vorolanib in Ophthalmology 2 (DAVIO 2) clinical trial of EYP-1901, an investigational sustained delivery antivascular endothelial growth factor (anti-VEGF) treatment for wet
- Lenstec Receives FDA Approval for the SBL-3 Multifocal IOLhttps://modernod.com/news/lenstec-receives-fda-approval-for-sbl-3-multifocal-iol/2481002/Lenstec Announced that its SBL-3 IOL has been approved by the FDA. The SBL-3 IOL (Segmented Bifocal Lens) is a next-generation asymmetric multifocal refractive IOL that provides patients with near, intermediate and distance vision. Its patented design allows for improved contrast sensit
- LKC Appoints New Members of Sales and Marketing Leadershiphttps://modernod.com/news/lkc-appoints-new-members-of-sales-and-marketing-leadership/2480999/LKC Technologies, a provider of electroretinography devices, announced the hiring of two industry professionals to lead their strategic efforts to expand its foothold in the US optometric market. Gary VanMatre was appointed Vice President, US Sales, and will lead a geographica
- EyeCare Partners Expands Presence in Virginia with Two Acquisitionshttps://modernod.com/news/eyecare-partners-expands-presence-in-virginia-with-two-acquisitions/2480998/EyeCare Partners (ECP) announced it has entered into an agreement to partner with Commonwealth Eye Care Associates (CECA) and Retina Institute of Virginia (RIV). Financial terms of the deals were not disclosed. Through the partnership with Commonwealth Eye Care Associates, ECP
- Pixium Vision Announces Successful Implantation of First Patient in the Netherlands in Prima System European Pivotal Trial PRIMAverahttps://modernod.com/news/pixium-vision-announces-successful-implantation-of-first-patient-in-the-netherlands-in-prima-system-european-pivotal-trial-primavera/2480993/Pixium Vision announced the successful implantation of the first patient in the Netherlands in the PRIMAvera pivotal trial in atrophic dry age-related macular degeneration (AMD). This follows approval of the PRIMAvera study by the Dutch Ministry of Health, Welfare and Sport and the open
- Mobile OptiX Promotes Lorena Brownell to Presidenthttps://modernod.com/news/mobile-optix-promotes-lorena-brownell-to-president/2480991/Lorena Brownell has been promoted to President of mobile ophthalmology/optometry practice Mobile OptiX. Ms. Brownell joined Mobile OptiX in 2019 and most recently served as Director of Operations, Ms. Brownell brings 15 years of management, operations, and human resources expe
- RD Fund Announces New Chair and Expansion of Board of Directorshttps://modernod.com/news/rd-fund-announces-new-chair-and-expansion-of-board-of-directors/2480990/The RD Fund (Retinal Degeneration Fund)—the venture arm of the Foundation Fighting Blindness aimed at driving research toward preventions, treatments, and cures for the entire spectrum of retinal degenerative diseases—announced the appointment of Adrienne Graves, P
- Clearside Biomedical Completes Dosing in OASIS Phase 1/2a Clinical Trial of CLS-AX in Wet AMD Patientshttps://modernod.com/news/clearside-biomedical-completes-dosing-in-oasis-phase-12a-clinical-trial-of-cls-ax-in-wet-amd-patients/2480989/Clearside Biomedical announced today completion of dosing in Cohorts 3 and 4 of OASIS, its phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) in patients with wet age-related macular degeneration (AMD). OASIS is a US-based, multicen